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ORIGINAL ARTICLEUnusual staphylococcal toxic shock syndrome presenting as a scarlet-like
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France and 5) St Helens Clinical Commissioning Group, United KingdomAbstractDiagnosis of nonmenstrual staphylococcal toxic shock syndrome (TSS) is often challenging. A female medical colleague had a rare entity, a
staphylococcal pharyngitis complicated by TSS. The diagnosis was conﬁrmed by isolation of tst-positive Staphylococcus aureus in throat culture
and by identiﬁcation of a speciﬁc Vβ2 expansion pattern of her T lymphocytes. Recent improvements in microbiology can be of great help for
the diagnosis of nonmenstrual TSS.
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E-mail: diego.andrey@hcuge.chCase descriptionWe report the case of a healthy 32-year-old female colleague,
who was admitted to our hospital in septic shock with high
fever (40°C), tachycardia and hypotension, with no response to
ﬂuid resuscitation and antibiotic therapy. Her symptoms started
4 days before with isolated sore throat (no rhinitis or cough)
followed by erythroderma (Fig. 1). The day before admission,
her husband—an infectious disease specialist—prescribed her
amoxicillin 1 g three times a day, suspecting Streptococcus pyo-
genes pharyngitis.
At admission, her main complaints were persistent severe
throat pain, fever and onset of a generalized rash (Fig. 1(A)). She
is a mother of two healthy children and had no other relevant
contact history. Physical examination revealed erythrodermia,w Microbe and New Infect 2015; 8: 10–13
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p://dx.doi.org/10.1016/j.nmni.2015.08.002enanthema and pustular lesions of the oropharynx and poste-
rior pillars bilaterally. Tonsils were erythematous, as was the
hypopharynx and larynx. No oedema or abscesses were
observed. A thorough systematic assessment did not reveal any
other site of infection, in particular no sign of fasciitis or
myositis, and no gynecologic symptoms (discharge, pain or
menstruation) were present.
Direct antigenic StrepA detection tests were performed
twice but remained negative despite our initial clinical suspicion
of streptococcal scarlet fever. Throat swabs were performed
and the samples cultured. Microscopic examination of the urine
was normal, and blood cultures were performed.
Laboratory results were as follows: leukocyte count 9.5 g/Lwith
51% band forms and absolute lymphopenia (0.1 g/L). Hemoglobin
was 129 g/L, and thrombocytes were 153 g/L. Blood smear
revealed band forms and vacuolated neutrophils with Döhle
bodies. C-reactive protein was elevated, at 483 mg/L, and pro-
calcitonin was 2.97 μg/L. Serum creatinine was elevated, at
121 μmol/L, with an estimated (Modiﬁcation of Diet in Renal
Disease study equation) creatinine clearanceof 44mL/min/1.73m3.
Liver function tests were normal. Coagulation prothrombin ratio
was 62%, and partial thromboplastin time was 47 seconds.European Society of Clinical Microbiology and Infectious Diseases
nses/by-nc-nd/4.0/)
FIG. 1. Classical staphylococcal toxic shock syndrome rash (A) followed by palm desquamation at day 7 (B).
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intravenously once daily in the emergency room. Intravenously
administered clindamycin 900 mg TID (three times a day) was
added 3 hours later when the patient was seen by the infectious
disease specialist because of new instability. A switch from
ceftriaxone to imipenem 750 mg four times a day (with clin-
damycin) was made in the intensive care unit while admitting
the patient for refractory hypotension requiring aminergic
(norepinephrine) support. The latter was needed for 12 hours
only, as the patient rapidly improved.
The throat swab obtained at admission grew a methicillin-
susceptible Staphylococcus aureus (MSSA), whereas all other
cultures (blood and urine) remained negative. We suspected
staphylococcal toxic shock syndrome (TSS) resulting from
pharyngitis, and we tested the MSSA strain positive for tst
encoding TSST-1 (toxic shock syndrome toxin 1). Analysis of
the Vβ proﬁle of T lymphocytes of the patient’s blood was
performed. The analysis covers the 24 more frequent Vβ
proﬁles by IO Test Beta Mark and FACScan cytometry
(Becton Dickinson, Franklin Lakes, NJ, USA). The results
revealed a unique strong expansion of the Vβ2 subset of T
lymphocytes (23%; normal range, 5.8–10.6%), conﬁrming that
TSST-1 was produced and was responsible for the clinical
disease in our patient. Antistreptolysin O (ASLO) testing,
performed in the context of the initial suspicion of scarlet
fever, was measured at day 1 and 1 week later, and remained
negative. A serologic panel for a “mononucleosis syndrome”
was negative for HIV and cytomegalovirus (including viraemia)
and positive for Epstein-Barr virus (previous infection). The
patient strain of MSSA was resistant to clindamycin, and she
was discharged with oral amoxicillin–clavulanate. Desqua-
mation of her palms occurred at day 7 (Fig. 1(B)). Her re-
covery was complete, with disappearance of fever, throat pain
and rash.New Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on beha
This is an open access artiDiscussionWe describe a rare case of staphylococcal pharyngitis compli-
cated with TSS in a female colleague. The direct antigen
detection kits for StrepA are known to be of moderate clinical
sensitivity (70–90%) [1]. Throat culture remains the reference
standard to diagnose group A Streptococcus (GAS) infections,
with a sensitivity of 90–95% when performed properly [1];
both these tests remained negative for GAS.
Staphylococcal TSS was diagnosed as a result of the presence
of a toxic shock and of a positive throat culture for a S. aureus
encoding the tst gene. The Vβ2 lymphocytes’ unique expansion
pattern conﬁrmed the signature of TSST-1 because Vβ’s mul-
tiple other expansion patterns are generally observed with
other staphylococcal or streptococcal superantigens [2,3].
Although the Vβ2 proﬁle is not 100% speciﬁc (the SpeC toxin
of Streptococcus pyogenes is responsible for a Vβ2 pattern), the
combination of this Vβ2 subset, associated with the isolation of
a tst-positive MSSA and the lack of ASLO, allowed us to
conclude that this “scarlet fever” complicated by TSS was
indeed due to MSSA. Because the patient presented desqua-
mation 1 week after onset of symptoms, her disease met the US
Centers for Disease Control and Prevention (CDC) diagnostic
criteria for probable TSS: high fever, rash, desquamation, hy-
potension, only two organ failures (acute kidney injury,
impaired coagulation), for 4/5 criteria. Nonmenstrual TSS
(nmTSS) resulting from a staphylococcal pharyngitis was our
ﬁnal diagnosis. The molecular analysis of S. aureus strain was tst
positive. The strain belonged to agr type 3 and was tested as
eta/etb and pvl negative (encoding exfoliatins and Panton-
Valentine leukocidin, respectively).
Clinical TSS was ﬁrst described by Todd et al. in 1978 [4].
TSS became a public health issue in 1980 when a menstrual TSSlf of European Society of Clinical Microbiology and Infectious Diseases, NMNI, 8, 10–13
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diffusion of TSST-1 occurred after S. aureus vaginal colonization.
nmTSS are generally observed in the context of surgical site
infection, postpartum or from cesarean section wound infec-
tion, burns, cutaneous lesions, arthritis or osteomyelitis, and is
due to the systemic diffusion of TSST-1 or enterotoxins (the
latter do not efﬁciently cross the mucosal barrier) [5]. Upper
respiratory viral illness complicated by S. aureus TSS has been
identiﬁed and is called postinﬂuenza TSS, although no speciﬁc
tests were available at the time to conﬁrm this diagnosis [6].
This severe condition has mainly been reported in association
with suppurative tracheitis and pneumonia [7]. Of note, nmTSS
could be a form of frontier between TSS and septic shock if the
patient has a suppurative primary site of infection and/or if
blood cultures grow S. aureus. (TSST-1 or enterotoxins
participate in the inﬂammatory response with peptidoglycan
and common staphylococcal toxins such as hemolysin α.) In
children, TSS has already been described as a complication of
staphylococcal rhinolaryngologic infections or surgery [8], and
more rarely pharyngitis [3]. In children, staphylococcal scarlet
fever has been used to describe incomplete, mild forms of TSS
after S. aureus pharyngeal colonization; these cases generally
lack hypotension and have rash as the predominant sign [9]. A
similar mild form of nmTSS due to TSST-1 has also been
described in neonates, called neonatal TSS-like exanthematous
disease, which is associated with systemic diffusion of TSST-1
associated with the expansion of Vβ2 [10]. In adults, S. aureus
pharyngitis complicated with TSS has not been described. This
shows how exceptional it is compared to streptococcal TSS
due to the TSS toxin– like superantigen of GAS.
The CDC have deﬁned speciﬁc criteria for probable and
deﬁnite TSS, including high fever, rash, hypotension, multi-
system disease and desquamation in association with the
absence of microbiologic criteria for alternative disease
[11–13]. Although desquamation is probably the most speciﬁc
clinical ﬁnding, it arises several days after the onset of the dis-
ease, so it is not useful for early diagnosis. Acute and conva-
lescent antibody testing can help establish the diagnosis,
although several series have shown an inability of some patients
to increase serologic titles after the disease; this inability gives
rise to recurrent TSS in some patients [14].
The CDC diagnostic criteria were established mainly for
epidemiologic surveillance purposes, and no positive micro-
biologic or serological/immunologic criteria are included [13].
The isolation of a S. aureus strain carrying genes coding for
superantigenic toxins, together with the identiﬁcation of a
speciﬁc Vβ T lymphocytes expansion pattern, are probably the
most useful complementary tests to conﬁrm the clinical sus-
picion of staphylococcal TSS in an acute setting. Availability of
these results in 24 hours allows a prompt, decisiveNew Microbes and New Infections © 2015 The Authors. Published by Elsevier Ltd on behalf of
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/liceconﬁrmation of the diagnosis and favours the addition of
clindamycin in this type of clinical setting. Although the clinical
CDC criteria remain the main pillars for the diagnosis of TSS,
the addition of these microbiologic and immunologic diag-
nostic tests in deﬁned situations can be of great help for the
diagnosis of nmTSS.Conﬂict of interestGL has received research funding from Pﬁzer, bioMérieux and
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